CELL ENGAGING BINDING MOLECULES
The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL)regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) r...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | PARK BUMAN PARK YOUNG-WOO JANG SE-IL |
| description | The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL)regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv regionso that the binding molecule binds to two different antigens.
本公开广泛地涉及癌症免疫治疗领域。例如，本公开一般涉及结合分子，所述结合分子包括抗体可变轻链(VL)区、可变重链(VH)区、恒定重链1(CH1)区和轻链恒定(CL)区，其配置形成两个抗原结合Fab区和一个抗原结合Fv区，使所述结合分子结合两种不同的抗原。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN112074540A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN112074540A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN112074540A3</originalsourceid><addsrcrecordid>eNrjZJB3dvXxUXD1c3d09_RzV3Dy9HMB0b7-Pq7OoT6uwTwMrGmJOcWpvFCam0HRzTXE2UM3tSA_PrW4IDE5NS-1JN7Zz9DQyMDcxNTEwNGYGDUAutghWg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CELL ENGAGING BINDING MOLECULES</title><source>esp@cenet</source><creator>PARK BUMAN ; PARK YOUNG-WOO ; JANG SE-IL</creator><creatorcontrib>PARK BUMAN ; PARK YOUNG-WOO ; JANG SE-IL</creatorcontrib><description>The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL)regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv regionso that the binding molecule binds to two different antigens.
本公开广泛地涉及癌症免疫治疗领域。例如，本公开一般涉及结合分子，所述结合分子包括抗体可变轻链(VL)区、可变重链(VH)区、恒定重链1(CH1)区和轻链恒定(CL)区，其配置形成两个抗原结合Fab区和一个抗原结合Fv区，使所述结合分子结合两种不同的抗原。</description><language>chi ; eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201211&DB=EPODOC&CC=CN&NR=112074540A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201211&DB=EPODOC&CC=CN&NR=112074540A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PARK BUMAN</creatorcontrib><creatorcontrib>PARK YOUNG-WOO</creatorcontrib><creatorcontrib>JANG SE-IL</creatorcontrib><title>CELL ENGAGING BINDING MOLECULES</title><description>The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL)regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv regionso that the binding molecule binds to two different antigens.
本公开广泛地涉及癌症免疫治疗领域。例如，本公开一般涉及结合分子，所述结合分子包括抗体可变轻链(VL)区、可变重链(VH)区、恒定重链1(CH1)区和轻链恒定(CL)区，其配置形成两个抗原结合Fab区和一个抗原结合Fv区，使所述结合分子结合两种不同的抗原。</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB3dvXxUXD1c3d09_RzV3Dy9HMB0b7-Pq7OoT6uwTwMrGmJOcWpvFCam0HRzTXE2UM3tSA_PrW4IDE5NS-1JN7Zz9DQyMDcxNTEwNGYGDUAutghWg</recordid><startdate>20201211</startdate><enddate>20201211</enddate><creator>PARK BUMAN</creator><creator>PARK YOUNG-WOO</creator><creator>JANG SE-IL</creator><scope>EVB</scope></search><sort><creationdate>20201211</creationdate><title>CELL ENGAGING BINDING MOLECULES</title><author>PARK BUMAN ; PARK YOUNG-WOO ; JANG SE-IL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN112074540A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>PARK BUMAN</creatorcontrib><creatorcontrib>PARK YOUNG-WOO</creatorcontrib><creatorcontrib>JANG SE-IL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PARK BUMAN</au><au>PARK YOUNG-WOO</au><au>JANG SE-IL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CELL ENGAGING BINDING MOLECULES</title><date>2020-12-11</date><risdate>2020</risdate><abstract>The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL)regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv regionso that the binding molecule binds to two different antigens.
本公开广泛地涉及癌症免疫治疗领域。例如，本公开一般涉及结合分子，所述结合分子包括抗体可变轻链(VL)区、可变重链(VH)区、恒定重链1(CH1)区和轻链恒定(CL)区，其配置形成两个抗原结合Fab区和一个抗原结合Fv区，使所述结合分子结合两种不同的抗原。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN112074540A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CELL ENGAGING BINDING MOLECULES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PARK%20BUMAN&rft.date=2020-12-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN112074540A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |